AVZO-021

N/A

Report date: 2025/01/14 16:41:57
NME

Base Information

Drug NameAVZO-021
Drug Alias NameARTS-021AVZO-021
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 2 inhibitors
TargetsCyclin-dependent kinase 2
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursEndometrial Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAllorion Therapeutics Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAvenzo Therapeutics IncAnrui Biomedical Technology (Guangzhou) Co Ltd
Inactive CompaniesAllorion Therapeutics Inc
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursEndometrial Neoplasms +[10] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A